Table 3.
With and without cancer (%) | With cancer (%) | Without cancer (%) | With and without cancer (%) | With and without cancer (%) | |
---|---|---|---|---|---|
aCGA |
CUT-OFF ≥ 1 |
|
|
CUT-OFF ≥ 2 |
|
Sensitivity |
85 (81 – 88) |
79 (71 – 87) |
87 (83 – 91) |
58 (53 – 63) |
|
Specificity |
63 (58 – 68) |
59 (50 – 68) |
64 (59 – 70) |
94 (91 – 96) |
|
PPV |
68 (64 – 73) |
64 (55 – 73) |
70 (65 – 75) |
90 (87 – 93) |
|
NPV |
82 (78 – 85) |
75 (67 – 83) |
84 (80 – 88) |
70 (66 – 75) |
|
Classified as frail |
60 |
59 |
61 |
31 |
|
VES-13 |
CUT-OFF ≥ 3 |
|
|
CUT-OFF ≥ 2 |
CUT-OFF ≥ 4 |
Sensitivity |
78 (74 – 82) |
67 (58 – 76) |
82 (77 – 86) |
81 (77 – 85) |
74 (70 – 78) |
Specificity |
76 (72 – 80) |
70 (61 – 78) |
79 (74 – 83) |
69 (65 – 74) |
78 (74 – 82) |
PPV |
75 (71 – 80) |
67 (58 – 76) |
78 (73 – 83) |
71 (67 – 76) |
76 (72 – 80) |
NPV |
78 (74 – 82) |
70 (61 – 78) |
82 (77 – 86) |
79 (75 – 83) |
76 (72 – 80) |
Classified as frail |
50 |
48 |
51 |
55 |
47 |
GFI |
CUT-OFF ≥ 4 |
|
|
CUT-OFF ≥ 3 |
CUT-OFF ≥ 5 |
Sensitivity |
76 (71 – 86) |
79 (61 – 87) |
74 (69 – 79) |
88 (84 – 91) |
59 (54 – 63) |
Specificity |
73 (68 – 77) |
71 (63 – 80) |
73 (68 – 78) |
49 (44 – 54) |
83 (79 – 87) |
PPV |
72 (68 – 77) |
72 (63 – 80) |
72 (67 – 78) |
62 (57 – 67) |
76 (72 – 81) |
NPV |
76 (72–80) |
78 (71 – 86) |
75 (70 – 80) |
81 (77 – 85) |
68 (63 – 73) |
Classified as frail |
51 |
53 |
50 |
69 |
37 |
G8 |
CUT-OFF ≤ 14 |
|
|
CUT-OFF ≤ 13 |
CUT-OFF ≤ 15 |
Sensitivity |
78 (74 – 82) |
87 (80 – 93) |
75 (70 – 80) |
61 (56 – 65) |
96 (94 – 98) |
Specificity |
68 (63 – 72) |
64 (55 – 73) |
69 (64 – 74) |
86 (82 – 89) |
39 (34 – 44) |
PPV |
70 (65 – 74) |
69 (61 – 78) |
70 (64 – 75) |
80 (76 – 84) |
60 (55 – 65) |
NPV |
77 (73 – 81) |
84 (77 – 91) |
75 (70 – 80) |
70 (65 – 74) |
91 (88 – 94) |
Classified as frail | 55 | 60 | 52 | 37 | 78 |